Pilot study demonstrates ParActin’s potential in the fight against Alzheimer’s AD is a particularly heartwrenching disease, as the mental decline seems inevitable and irreversible—we literally have to watch our loved ones disappear right in front of us. So even slowing things down is considered a victory… and turning things around could be cause for celebration. To see how well ParActin could work for people with AD, Dr. Hancke’s team recruited 20 patients, all in the early stages of the disease. All of the patients underwent standard psycho-neurological testing by neurophysiologists who were unaware of the treatment being given. The patients were split into two groups, one treated with 250 mg of ParActin twice daily, and the other placebo. Sadly, at the end of the three-month trial, the patients in the placebo group showed significant cognitive decline—the normal course of this disease. But the patients treated with ParActin had statistically improved test scores. And for a disease where treatment that slows things down is considered a rousing success, this could signal a real breakthrough for Alzheimer’s patients. That’s why the research is ongoing—and we’ll let you know as soon as more results are in. And while we’re waiting to see just how successful ParActin may be for AD patients, we know it’s already proven effective in autoimmune diseases… like rheumatoid arthritis. ParActin safely and significantly reduces pain for rheumatoid arthritis patients Broken down cartilage, eroding bones, misshapen joints—these horrific symptoms all come with rheumatoid arthritis (RA), an autoimmune condition where your body literally attacks itself with uncontrolled inflammation. That inflammation gets triggered by specific compounds created by your immune system: COX-2, TNFα (tumor necrosis factor alpha), and IL-2 (interleukin 2)… all of which can be mediated by ParActin. We first told you about its antiinflammatory factors back in 2006, when the science on ParActin’s actions was conducted in the lab. Now, we have human studies to show the true impact of this miracle extract on painful swollen joints. The work started with two small pilot studies. In the first, 10 earlystage RA patients were given 200 mg of ParActin once a day for 18 weeks. Blood was drawn and tested at the start, and again several times during the study to monitor values. And by the end of the study period, virtually all of the values had improved, including C-reactive protein (CRP), a critical inflammation marker. The second pilot study pitted ParActin against NSAIDs for a 6-week study that included 14 RA patients. After the first two weeks of treatment, the ParActin group was experiencing a bigger decrease in pain than the NSAID group (though the NSAID group caught up by week five). But where the science really stands by ParActin was in a randomized, double-blind, placebo-controlled study of 85 RA patients.2 Patients in this 14-week study took either 255 mg of ParActin daily (split into 3 doses) or placebo. They were given ‘rescue’ pain medication (NSAIDs or acetaminophen) as needed throughout the trial. And the results showed once and for all just how effective ParActin is for RA treatment. • The placebo group used rescue medicine over 55% of the trial… compared to just 5% of the time for the ParActin group • The ParActin group enjoyed a much more significant decrease in painful joints, despite the fact that the placebo group took more pain medication • The patients in the ParActin group experienced a substantial reduction in fatigue, while the placebo group saw no improvement at all • And for those of you who like clear statistics, ParActin brought on a 40-point drop in Rheumatoid Factor, a key indicator of autoimmune disease, while the placebo group saw (continued on next page) HSI-0412.indd 3 2/23/12 2:37 PM Members Alert • April 2012 4 Visit us online at www.HSIonline.com Hidden treatment for incurable diseases (like Alzheimer’s and MS) (continued from page 3) no significant change (despite the fact they were taking more NSAIDs during the trial period) The patients in the placebo group not only felt better, they got measurably better—without any of the severely damaging potential side effects that come with most of the pharmaceutical treatment options. After just 6 months on ParActin, MS sufferers see extreme improvement in symptoms Realizing that andrographis could tame autoimmune responses, researchers set out to see if it could work for multiple sclerosis (MS) patients. So they started with animals, special mice given a condition called EAE, a model of human MS.3 The results were groundbreaking. Not only did the andrographis extract delay disease onset, it also significantly reduced both the incidence and severity of symptoms. The mice suffered fewer symptoms, had much milder symptoms, and got symptoms later than they would have without the treatment. But that’s not where this ends. A Chilean doctor, Dr. Juan Bertolglio of the Universidad Austral de Chile, ran two case studies on MS patients suffering debilitating symptoms. Each was giving 250 mg of ParActin for 6 months, and by the end of that time, both patients were able to stop taking prescription MS drugs. What’s more, some of their worst symptoms were alleviated: • Fatigue and sleep problems • Restless leg syndrome • Muscle jerking and twitching • Depression • L’Hermittes (electric shocklike sensations) Now I know that’s only two people and one mouse study, but the results are truly promising. And when you consider the debilitating symptoms of this incurable disease, and the sometimes even worse damaging side effects of prescription MS drugs (liver damage, increased risk of infection, blood cancers, and fatal brain infections, to name a few), ParActin just might be the safe treatment we’ve been hoping for. And it all started with a cure for the common cold.